Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Kodiak Sciences Inc. (KOD) Up 15.7% Since Last Earnings Report: Can It Continue?
It has been about a month since the last earnings report for Kodiak Sciences Inc. (KOD - Free Report) . Shares have added about 15.7% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Kodiak Sciences Inc. due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Kodiak Sciences Q2 Earnings Lag, Eye Candidate in Focus
Kodiak Sciences reported second-quarter 2021 loss per share of $1.08, wider than the Zacks Consensus Estimate of a loss of $1.04 and the year-ago loss of 58 cents.
Kodiak Sciences currently does not have any approved product in its portfolio. As a result, the company is yet to generate revenues.
Quarter in Detail
Research and development expenses were $45.4 million for the quarter, significantly up from $20.6 million in the year-ago period. The increase was driven by higher clinical activities related to KSI-301.
General and administrative expenses were $10.5 million, up 69.4% on a year-over-year basis.
As of Jun 30, 2021, Kodiak Sciences had cash worth $880.9 million compared with $929 million on Mar 31, 2021.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimates have trended upward during the past month. The consensus estimate has shifted 6.06% due to these changes.
VGM Scores
Currently, Kodiak Sciences Inc. has a poor Growth Score of F, however its Momentum Score is doing a lot better with a B. However, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Kodiak Sciences Inc. has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.